Monomethyl auristatin F (MMAF) is a synthetic antineoplastic agent. It is part of the approved drug belantamab mafodotin in multiple myeloma and some experimental anti-cancer antibody-drug conjugates such as vorsetuzumab mafodotin and SGN-CD19A. In International Nonproprietary Names for MMAF-antibody-conjugates, the name mafodotin refers to MMAF plus its attachment structure to the antibody. Monomethyl auristatin F is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin. It is linked to an antibody with high affinity to structures on cancer cells, causing MMAF to accumulate in such cells. MMAF is actually desmethyl-auristatin F; that is, the N-terminal amino group has only one methyl substituent instead of two as in auristatin F itself.
The binding activity of HA600035 with MMAF-ADC, MMAF-BSA, MMAE-BSA, DM1-ADC and BSA protein at 1 μg/ml overnight at 4℃. Then blocked with 1% BSA for 1 hour at 37℃, and incubated with the primary antibody (HA600035) for 1 hour at 25℃.
Mouse anti-MMAF Ab (HA600035) can bind to MMAF-ADC or MMAF-BSA but not BSA or MMAE-BSA.
Down ELISA Binding Assay of anti-MMAF Antibody A5G11(HA600035) to MMAF-ADC and MMAF-BSA. The mouse mAb works fine with ELISA assay for measuring MMAF derivative ADC.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"